Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IMNM 
Immunome Inc (IMNM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: IMNM (1-star) is a SELL. SELL since 2 days. Profits (-5.39%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $24.25
1 Year Target Price $24.25
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.24% | Avg. Invested days 21 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 865.23M USD | Price to earnings Ratio - | 1Y Target Price 24.25 |
Price to earnings Ratio - | 1Y Target Price 24.25 | ||
Volume (30-day avg) 9 | Beta 1.93 | 52 Weeks Range 5.15 - 16.73 | Updated Date 08/15/2025 |
52 Weeks Range 5.15 - 16.73 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.05 |
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.6218 | Actual -0.5 |
Profitability
Profit Margin - | Operating Margin (TTM) -1157.61% |
Management Effectiveness
Return on Assets (TTM) -40.2% | Return on Equity (TTM) -81.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 601333379 | Price to Sales(TTM) 68.73 |
Enterprise Value 601333379 | Price to Sales(TTM) 68.73 | ||
Enterprise Value to Revenue 47.77 | Enterprise Value to EBITDA -0.72 | Shares Outstanding 87045000 | Shares Floating 70644858 |
Shares Outstanding 87045000 | Shares Floating 70644858 | ||
Percent Insiders 11.47 | Percent Institutions 90.31 |
Upturn AI SWOT
Immunome Inc
Company Overview
History and Background
Immunome, Inc. was founded in 2012. It is a biotechnology company focused on developing first-in-class and best-in-class antibody therapeutics.
Core Business Areas
- Drug Discovery and Development: Immunome focuses on discovering and developing novel antibody therapeutics for oncology and infectious diseases. They use their proprietary human memory B cell platform to identify antibodies with unique binding specificities and therapeutic potential.
Leadership and Structure
The company is led by a management team with experience in drug development and biotechnology. Purnanand Sarma is the President and CEO. The company has a board of directors overseeing its operations.
Top Products and Market Share
Key Offerings
- IMM-ONC-001: This is Immunome's lead oncology program. It is a novel antibody targeting solid tumors. It is currently in Phase 1 clinical trials. Competitors include companies developing similar antibody-based therapies for solid tumors.
- IMM-BCP-01: IMM-BCP-01 is an antibody cocktail targeting SARS-CoV-2. It is designed to neutralize multiple variants of the virus. Market share data is not publicly available. Competitors include Regeneron and Eli Lilly.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, long development timelines, and regulatory hurdles. Competition is intense, and success depends on scientific innovation and clinical trial outcomes.
Positioning
Immunome is a relatively small biotechnology company focused on antibody therapeutics. Its competitive advantage lies in its proprietary human memory B cell platform, which allows it to discover novel antibodies that may have unique therapeutic properties.
Total Addressable Market (TAM)
The TAM for antibody therapeutics is substantial and continues to grow. Immunome's positioning with respect to this TAM is focused on specific oncology targets and infectious diseases where it believes it can differentiate itself through novel antibody discovery.
Upturn SWOT Analysis
Strengths
- Proprietary human memory B cell platform
- Novel antibody discovery capabilities
- Focus on oncology and infectious diseases
- Experienced management team
Weaknesses
- Limited financial resources
- Early-stage clinical programs
- Reliance on clinical trial success
- Small market capitalization
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through new antibody discoveries
- Acquisition by a larger company
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- REGN
- LLY
- MRNA
- PFE
Competitive Landscape
Immunome's competitive advantage is its novel antibody discovery platform. However, it faces significant competition from larger pharmaceutical companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to its stage as a research-driven entity. Any revenue would likely be milestone based and limited in scope.
Future Projections: Future growth depends on the success of its clinical programs and its ability to secure partnerships. Analyst estimates vary widely based on clinical trial progress.
Recent Initiatives: Recent strategic initiatives focus on advancing its lead oncology and infectious disease programs through clinical trials.
Summary
Immunome is an early-stage biotechnology company with a promising antibody discovery platform. Its success hinges on positive clinical trial outcomes and strategic partnerships to fund its development programs. The company faces significant competition from larger, more established pharmaceutical companies. Early stage companies can be highly sensitive to market sentiment and capital raising activities. It needs to develop key product market fit to create revenue.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Immunome, Inc. SEC filings
- Company Website
- Third-party market research reports
- Financial news sources
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is subject to rapid change, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immunome Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 2020-10-02 | Chairman, President & CEO Dr. Clay B. Siegall Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 155 | Website https://immunome.com |
Full time employees 155 | Website https://immunome.com | ||
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.